A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

NCT01082315 · clinicaltrials.gov ↗

COMPLETED

Status

730

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: Erbitux (Cetuximab)

Sponsor

Merck KGaA, Darmstadt, Germany